🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Now in The Lancet Rheumatology-Reasoning LLMs in #Rheumatology: Pearl's ladder of causation shows the gap bw AI's statistical patterns & true counterfactual reasoning- A rheumatologist weighing TNFi risks vs. delayed treatment needs reasoning that AI fundamentally lacks. Vincenzo Venerito

Terms anti-synthetase syndrome and ASyS proposed as standard nomenclature and abbreviation in research and clinical practice

𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗮𝗹𝗴𝗼𝗿𝗶𝘁𝗵𝗺 𝗳𝗼𝗿 𝗜𝗴𝗚𝟰-𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝗱𝗶𝘀𝗲𝗮𝘀𝗲. This flowchart provides a structured approach to the treatment of #IgG4-related disease, guiding therapeutic decisions on the basis of clinical presentation and response to therapy. Initial

Glucocorticoids in SLE: how to start, how to follow, how to stop More than 70 years after their first use in rheumatology by Philip Hench, glucocorticoids (GCs) continue to be one of the main weapons to fight systemic lupus erythematosus (SLE). No other available medication

🚨 #Lupus is a complex and heterogeneous systemic autoimmune disease in which the body's immune system attacks your own tissues and organs, causing inflammation and damage in any part of the body Visit #Lupus100 & #LupusGPT for more! #WorldLupusDay #MakeLupusVisible

On May 10th, we come together to recognize and show support for those affected by SLE. Join our activities to get more involved in the care of this complex autoimmune disease. Discover more: sleuro.org Become a member for free here: sleuro.org/membership/

Today is #WorldLupusDay ! Lupus is a chronic autoimmune disease that can affect skin, joints, kidneys, almost any organ in the body. Let’s support those impacted and advocate for better care. Better awareness - earlier care - better lives. #LupusAwareness #WorldLupusDay2025

New Steroid Rules in Lupus? Let’s Talk. Dr. Michelle Petri breaks down the latest strategies to minimize steroid exposure while managing disease activity in lupus patients. 💡 Smarter steroid use = better outcomes. 👉 Watch now on RheumNow: buff.ly/QawYMse #Lupus

🧬GWAS study found that asymptomatic ANA positivity is not associated with increased cumulative genetic risk for lupus compared to ANA-negative. 👉This suggests that ANA production is primarily influenced by environmental exposures. #GWAS #Lupus #Genetics pmc.ncbi.nlm.nih.gov/articles/PMC11…

✨Study from Italy shows that achieving 3 years of remission in patients with LN significantly reduces the risk of impaired kidney function and SLICC damage index accrual. 🎯This threshold of remission could serve as a safe treatment goal in LN. ard.eular.org/article/S0003-…

🧵1/ Yesterday, I saw a young woman with SLE & lupus nephritis, on steroids + mycophenolate, who came in with sudden right hip pain radiating to the knee. She could barely walk. What’s your first thought? 👉 AVN – Avascular Necrosis of the femoral head. AVN is common in: •

A retrospective VEXAS cohort study of 59 pts receiving 71 targeted Rx - 98%male, mean 71 yrs & 46% had myelodysplastic syndr. Treatments included tocilizumab(19), anakinra (13), azacitidine(13), baricitinib (11), & pred only (10). Best responses w/ azacitidine & tocilizumab

Do SGLT2 and GLP-1 therapies have a role in Lupus? Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP1-RA), initially developed to lower glucose in Type 2 Diabetes, also provide cardiovascular and renal protection for patients

Less than ONE MONTH LEFT to pre-register for the 7th SLEuro Advanced Workshop on SLE! 📍 Tallinn, Estonia 🗓️ 12-13 September 2025 ⏰ Deadline: 15th July 2025 Pre-register here (SLEuro membership required): services.aimgroup.eu/ASPClient/home… 🌐: sleuro.org/future-worksho…

Efficacy of lifestyle interventions in the management of systemic lupus erythematosus: a systematic review… Laurent ARNAUD Ioannis Parodis Lupus Foundation of America Lupus Research Panlar PANLAR joven EMEUNET Genç TRASD pubmed.ncbi.nlm.nih.gov/38451302/

📌Study from UK by Prof.Savic & colleagues offers comprehensive analysis of outcomes of 🎯 therapies in VEXAS sy 👉 azacitidine and tocilizumab were superior to anakinra, baricitinib, prednisolone 💡azacitidine showed a potential disease-modifying role thelancet.com/journals/lanrh…

Excellent summary by Antonis Fanouriakis at #eular2025 on recent advances in #SLE—covering pathogenesis, treatment strategies, and key trials from 2024–2025

✨ New insight into autoimmune CHB could transform risk stratification and early detection! Novel maternal autoantibody targeting fetal AT1A1🫀protein identified as a potential biomarker for CHB in pregnancies without prior affected children #CHB #Lupus thelancet.com/journals/lanrh…